Using assays for 2D and 3D growth, we found no evidence that bevacizumab or the VEGFR inhibitor AZD2171 (cediranib) inhibited the growth of human BRAFV600E or BRAFWT melanoma cells (Appendix Fig. S1A-C). Here, KDR is linked to melanoma.